GSK plc 6-K, filed Jul 1, 2022
GSK plc (GSK)
6-K
2022-07-01
For: 2022-07-01
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on July 1, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 1 July 2022, London UK
GSK completes acquisition of Sierra Oncology
GSK plc (LSE/NYSE: GSK) today announced it has completed the
acquisition of Sierra Oncology, Inc. (Sierra Oncology), a
California-based biopharmaceutical company focused on targeted
therapies for the treatment of rare forms of cancer. The
acquisition was approved by Sierra Oncology's shareholders on 29
June 2022.
As previously
announced, the acquisition of
Sierra Oncology includes momelotinib, a late-stage potential new
medicine with a unique dual mechanism of action that may address
the critical unmet medical needs of myelofibrosis patients with
anaemia. In addition, momelotinib complements
GSK's Blenrep (belantamab mafodotin); the acquisition
builds on the company's expertise in haematology and aligns with
GSK's strategy of building a strong portfolio of specialty
medicines and vaccines. If approved, momelotinib will contribute to
GSK's growing specialty medicines business, with a US launch
anticipated in 2023.
Luke Miels, Chief Commercial Officer, GSK, said: "This
acquisition expands our innovative oncology portfolio,
demonstrating our commitment to improving patient outcomes and
creating value for shareholders. We now have a
late-stage differentiated
molecule in momelotinib,
which could potentially address a significant
unmet need in myelofibrosis patients with anaemia. Our focus is now
on execution."
In June 2022, Sierra Oncology presented the complete data from the
MOMENTUM phase III trial at the 2022 American Society of Clinical Oncology
(ASCO) Annual Meeting. The
trial met all its primary and key secondary endpoints,
demonstrating that momelotinib achieved a statistically significant
and clinically meaningful benefit on symptoms, splenic response,
and anaemia. Sierra Oncology submitted a New Drug Application to
the US Food and Drug Administration in June, and GSK anticipates a
regulatory submission in Europe in the second half of
2022.
Financial considerations
Upon completion of the acquisition, GSK acquired all outstanding
shares of Sierra Oncology for $55 per share in cash, representing
an approximate total equity value of $1.9 billion (£1.6
billion at current exchange rates). The per-share price represented
a premium of approximately 39 per cent to Sierra Oncology's closing
stock price on 12 April 2022 and approximately 63 per cent to
Sierra's volume-weighted average price (VWAP) over the last 30
trading days.
About myelofibrosis
Myelofibrosis is a rare blood cancer that results from dysregulated
JAK-STAT signalling and is characterised by constitutional
symptoms, splenomegaly (enlarged spleen) and progressive anaemia.
From prior studies with momelotinib, we know approximately half of
myelofibrosis patients are moderately to severely anaemic when
eligible for JAK inhibitor treatment. Furthermore, currently
approved JAK inhibitors only address symptoms and splenomegaly and
are myelosuppressive. This can lead to worsening anaemia, resulting
in dose reductions that potentially reduce treatment
effect.
Myelofibrosis affects approximately 20,000 patients in the US, with
approximately 40% of patients already anaemic at time of diagnosis
and nearly all patients estimated to eventually develop
anaemia.[1],[2] Patients
treated with the most commonly used JAK inhibitor will often
require transfusions, and more than 30% will discontinue treatment
due to anaemia.[3] Anaemia
and transfusion dependence are strongly correlated with poor
prognosis and shortened survival.[4]
About momelotinib
Momelotinib has a differentiated mode of action with inhibitory
ability along three key signalling pathways: activin A receptor,
type I (ACVR1)/activin receptor-like kinase-2 (ALK2), Janus kinase
(JAK) 1, and JAK2. This activity may lead to beneficial treatment
effects on anaemia and reduce transfusion dependence while treating
myelofibrosis symptoms and splenic response.
GSK in oncology
GSK is focused on maximising patient survival through
transformational medicines. GSK's pipeline is focused on
immuno-oncology, cell therapy, tumor cell targeting therapies and
synthetic lethality. Our goal is to achieve a sustainable flow of
new treatments based on a diversified portfolio of investigational
medicines utilising modalities such as small molecules, antibodies,
antibody-drug conjugates and cell therapy, either alone or in
combination.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madeleine
Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1] Naymagon,
L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia:
Current and Emerging Therapeutic Strategies. HemaSphere, 1(1),
e1. https://doi.org/10.1097/HS9.0000000000000001
[2] Chifotides,
H.T., Bose, P. & Verstovsek, S. Momelotinib: an emerging
treatment for myelofibrosis patients with
anemia. J
Hematol Oncol 15, 7 (2022).
https://doi.org/10.1186/s13045-021-01157-4
[3] Palandri,
F., Palumbo, G.A., Elli, E.M. et al. Ruxolitinib
discontinuation syndrome: incidence, risk factors, and management
in 251 patients with myelofibrosis. Blood
Cancer J. 11, 4 (2021).
https://doi.org/10.1038/s41408-020-00392-1
[4] Pardanani,
A., & Tefferi, A. (2011). Prognostic
relevance of anemia and transfusion dependency in myelodysplastic
syndromes and primary myelofibrosis. Haematologica, 96(1), 8-10.
https://doi.org/10.3324/haematol.2010.035519
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
01, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|